SecBot SecBot
SECBOTREPLAY Home › Report › RARE

RARE · Ultragenyx settled patent litigation with Esjay Pharma over generic…

Ultragenyx Pharmaceutical Inc. · 8-K filed Aug 11, 2026 at 08:30 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Aug 11, 2026 at 08:30 ET

Ultragenyx settled patent litigation with Esjay Pharma over generic DOJOLVI (triheptanoin). Esjay gets a non-exclusive, royalty-free license to market its generic version starting January 1, 2033 (extended to July 1, 2033 if pediatric exclusivity is granted). The settlement removes near-term generic risk but sets a definitive loss of exclusivity date, while litigation against other ANDA filers remains pending. No financial terms were disclosed, and the agreement is subject to FTC/DOJ review.

  • Ultragenyx settled DOJOLVI patent litigation with Esjay Pharma on August 7, 2026.
  • Esjay receives a non-exclusive, royalty-free license to market generic DOJOLVI starting January 1, 2033 (or July 1, 2033 if pediatric exclusivity is granted).
  • Litigation against other ANDA filers for DOJOLVI remains pending in the District of New Jersey.
  • The settlement agreement will be submitted to the FTC and DOJ as required by law.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access